Illumina, Inc.
Real-time prices from Yahoo Finance's public feed. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All ILMN news ›Illumina SpliceAI2 Flags 17% More Disease Splice Variants
The Leading Source of Insights On Business Model Strategy & Tech Business Models, and a Top AI Business News Publication Illumina introduced SpliceAI2 on 8 October 2026, a genomic AI model that predicts how DNA variants change RNA…
Illumina releases SpliceAI2 to help advance rare disease research
In a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing models Illumina's genomic AI models now collectively enable researchers to identify 2x as many variants with predicted…
Illumina Inc (ILMN) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 65/100
On October 09, 2026, Illumina Inc ILMN shares rose 5.1% to a current price of $278.17, amidst a 52-week range of $88.00 to $309.35. The stock's strong performance over the past year, with a 188.4% increase, suggests significant market…
Illumina, Inc. Stock 12‑Month Price Target Raised to $237.16, Implies 10% Downside
TradingView Illumina, Inc. Stock 12‑Month Price Target Raised to $237.16, Implies 10% Downside - According to estimates from 19 analysts, Illumina, Inc. stock's average price target has risen from $235.68 to $237.16, with forecasts ranging…
Novacyt's strikes Illumina deal; Beeks' Thailand deal
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- Novacyt SA - biotechnology group focused on clinical... Biotechnology & Medical Research…
Why Illumina (ILMN) Stock Is Trading Up Today
Shares of genomics company Illumina (NASDAQ: ILMN) jumped 6.6% in the morning session after it appointed a high-profile Eli Lilly executive to its board and a price target increase from Barclays. Is now the time to buy Illumina? Access our…
What is Illumina’s (ILMN) Economic Moat, and is it Widening or Narrowing?
The money is in the reagents rather than the sequencers, and switching means revalidating every assay, which is worth a 67.93% gross margin. The moat is still wide and no longer prices freely, because revenue grew 9.40% while earnings fell…
Illumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
TRexBio Announces Pricing of Initial Public Offering Illumina (NASDAQ: ILMN) will release its third-quarter 2026 financial results after the market closes on October 29, 2026. CEO Jacob Thaysen and CFO Ankur Dhingra will discuss financial…
Illumina to release Q3 2026 earnings on Oct 29 with CEO and CFO hosting a call.
Illumina, a leader in DNA sequencing technology, will announce its third quarter 2026 financial results after market close on October 29, 2026. On the same day, CEO Jacob Thaysen and CFO Ankur Dhingra will hold a conference call at 1:30 pm…
Illumina, Inc. : Insider Transactions
Follow insider transactions on Illumina, Inc. in real time. Filter by importance or transaction type and analyze the history on MarketScreener. Insider Transactions Illumina, Inc. Advanced Medical Equipment & Technology Latest insider…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com49
-
stocktitan.net30
-
themarketsdaily.com22
-
tradingview.com22
-
gurufocus.com11
Measured across the 4Jogging news index. Headline tone is a simple word-based reading of the latest 120 headlines, not a forecast.